Adding a PD-1 inhibitor to standard of care improved disease-free survival (DFS) in stage III soft-tissue sarcoma of the extremity, a randomized trial showed. In patients with mostly undifferentiated ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

Iovance Biotherapeutics Inc. (NASDAQ:IOVA) is one of the best get-rich-quick stocks to buy according to hedge funds. On February 24, Iovance Biotherapeutics announced positive early data from a pilot ...

Against the backdrop of a case report, pembrolizumab was investigated as immunotherapy for undifferentiated pleomorphic soft tissue sarcoma. Noting that immunotherapy for soft tissue sarcoma (STS) has ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. A 56-year-old man presented to the ED with 3 months of ...

An expert writes about his experience as a sarcoma medical oncologist and how the field may progress with several therapies in the pipeline. As a sarcoma medical oncologist, the No. 1 question I am ...

In part 3 of an interview, MD Anderson’s Ravin Ratan, MD, MEd, discusses neoadjuvant immune checkpoint blockade for 2 specific types of soft tissue sarcomas. Liposarcomas originate in fat cells and ...

Please provide your email address to receive an email when new articles are posted on . A phase 2 trial conducted by researchers at The University of Texas MD Anderson Cancer Center demonstrated the ...

Success rates for drug development in solid tumors remain the lowest of the many therapeutics areas in medicine. Recent advances in drug discovery and development have transformed available therapies ...